| 09:00-09:10 | Opening Ceremony | |
| Symposium 1 | ||
|---|---|---|
| 09:10 - 11:10 | Public health response to COVID-19 | |
| Chair : | ||
| S1-1 | Public health response to COVID-19: National perspective
|
|
| S1-2 | Public health response to COVID-19: Regional perspective
|
|
| S1-3 | Public health response to COVID-19: Global perspective
|
|
| S1-4 | Strategies to flatten the curve: current evidence and practical pitfalls
|
|
| Symposium 2 | ||
|---|---|---|
| 09:10 - 11:10 | Gram-negative bacteria | |
| Chair : | ||
| S2-1 | Epidemiology and impact of carbapenem-resistant Acinetobacter and Pseudomonas
|
|
| S2-2 | Epidemiology and impact of carbapenem-resistant Enterobacterioceae
|
|
| S2-3 | Emergence of intrinsically resistant gram-negative bacteria: Stenotrophomonas, Burkholderia, and Chryseobacterium
|
|
| S2-4 | Antimicrobial therapy for carbapenem-resistant gram-negative bacteria
|
|
| Symposium 3 | ||
|---|---|---|
| 09:10 - 11:10 | How I treat difficult-to-treat infections (interactive) | |
| Chair : | ||
| S3-1 | How I treat persistent S. aureus bacteremia
|
|
| S3-2 | How I treat vascular graft infections
|
|
| S3-3 | How I treat refractory CMV infection
|
|
| Plenary Lecture 1 | ||
|---|---|---|
| 11:10 - 11:50 | ||
| Chair : | ||
| P-1 | Pandemic preparedness: are we ready for the future?
|
|
| Plenary Lecture 2 | ||
|---|---|---|
| 11:50 - 12:30 | ||
| Chair : | ||
| P-2 | Vaccines against SARS-CoV-2
|
|
| Satellite Symposium 1~3 | ||
|---|---|---|
| 13:30 - 15:00 |
| Plenary Lecture 3 | ||
|---|---|---|
| 15:10 - 15:50 | ||
| Chair : | ||
| P-3 | Overview of the current status of antimicrobial resistance
|
|
| Symposium 4 | ||
|---|---|---|
| 15:50 - 17:20 | Clinical management of COVID-19 | |
| Chair : | ||
| S4-1 | Therapeutic options for COVID-19
|
|
| S4-2 | Critical care of patients with severe COVID-19
|
|
| S4-3 | Long-term sequelae of COVID-19
|
|
| Symposium 5 | ||
|---|---|---|
| 15:50 - 17:20 | Diagnostics/clinical microbiology | |
| S5-1 | The future is here: rapid diagnosis of antimicrobial resistance
|
|
| S5-2 | Next-generation sequencing for diagnosis of infectious diseases
|
|
| S5-3 | How to combine novel techniques with stewardship: a real-world experience
|
|
| Symposium 6 | ||
|---|---|---|
| 15:50 - 17:20 | Antimicrobial stewardship | |
| Chair : (Move to Symposium 1) | ||
| S6-1 | Shorter the better: current evidence for the shorter duration of antibiotic therapy
|
|
| S6-2 | Incentives for antimicrobial stewardship: situation in Asia
|
|
| S6-3 | Antimicrobial stewardship during the COVID-19 pandemic |
|
| S6-4 | Antimicrobial stewardship during the COVID-19 pandemic
|
|
| Satellite Symposium 7~9 | ||
|---|---|---|
| 17:30 - 18:30 |
| Symposium 7 | ||
|---|---|---|
| 09:00 - 11:00 | Pros and cons (interactive) | |
| Chair : | ||
| S7-1 | Piperacillin-tazobactam for ESBL-producing Enterobacterales
|
|
| S7-2 | Early oral transition for endocarditis
|
|
| S7-3 | Combination regimen for carbapenem-resistant Acinetobacter infections
|
|
| Symposium 8 | ||
|---|---|---|
| 09:00 - 11:00 | Gram-positive bacteria | |
| Chair : | ||
| S8-1 | Update on antimicrobial resistance of Staphylococcus
|
|
| S8-2 | Antimicrobial resistance and treatment options for enterococcal infections
|
|
| S8-3 | How to dose vancomycin: time to go Bayesian?
|
|
| S8-4 | Novel, non-antibiotic therapeutic approaches to bacterial infection
|
|
| Symposium 9 | ||
|---|---|---|
| 09:00 - 11:00 | Infection prevention and control | |
| Chair : | ||
| S9-1 | Airborne, droplet, or something in between: physics of respiratory secretions
|
|
| S9-2 | Infection control for COVID-19: theory and practice
|
|
| S9-3 | Environmental cleaning & disinfection: current controversies
|
|
| S9-4 | Outbreak control in healthcare settings
|
|
| Plenary Lecture 4 | ||
|---|---|---|
| 11:10 - 11:50 | ||
| Chair : | ||
| P-4 | TBD |
|
| Plenary Lecture 5 | ||
|---|---|---|
| 11:50 - 12:30 | ||
| Chair : | ||
| P-5 | Promoting the development of novel therapeutic agents |
|
| Satellite Symposium 4~6 | ||
|---|---|---|
| 13:30 - 15:00 |
| Plenary Lecture 6 | ||
|---|---|---|
| 14:40 - 15:20 | ||
| Chair : | ||
| P-6 | Designing and conducting clinical trials that change the practice
|
|
| Symposium 10 | ||
|---|---|---|
| 15:50 - 17:20 | Fungus | |
| Chair : | ||
| S10-1 | Epidemiology and impact of anti-fungal resistance in Asia
|
|
| S10-2 | Endemic mycoses in the Asia-Pacific region
|
|
| S10-3 | Novel therapeutic options for invasive fungal infections
|
|
| S10-4 | |
|
| Symposium 11 | ||
|---|---|---|
| 15:50 - 17:20 | Vaccine | |
| Chair : | ||
| S11-1 | Future role of vaccines on antibacterial resistance | |
| S11-2 | Novel technologies for vaccine development | |
| S11-3 | Public communication regarding vaccines |
|
| Symposium 12 | ||
|---|---|---|
| 15:50 - 17:20 | HIV | |
| Chair : | ||
| S12-1 | Update on new strategies for antiretroviral therapy
|
|
| S12-2 | Diagnosis and treatment of HIV with complex resistance
|
|
| S12-3 | Disparities in PrEP access in the Asia Pacific |
|